



San Salvador, April 1<sup>th</sup> 2025

Dear WHO Expert Committee,

On behalf of Fundación Ayúdame a Vivir from El Salvador, a non-governmental organization dedicated to improving childhood cancer care in low- and middle-income countries, we are writing to express our strong support for the inclusion of blinatumomab on the WHO Model List of Essential Medicines for Children.

Blinatumomab has proven efficacy in treating children with relapsed or refractory B-ALL and has the potential to reduce treatment-related toxicity compared to traditional chemotherapy. However, this life-saving treatment remains out of reach for many due to cost and availability. Every year an average of 90 patients with B leukemia are diagnosed in our setting of these 30-40 will relapsed or will be present refractory disease and nowadays we have no chance to offer alternative treatments.

We believe that listing blinatumomab on the EML' c would send a powerful signal to national governments, procurement agencies, and donors, enabling access through global platforms and encouraging health system readiness , offering hope to many children and adolescent in our region.

Thank you for your consideration of this vital application

Sincerely

Roberto Franklin Vásquez

Fundación Ayúdame a Vivir Medical Director.

Head of Oncology Department, Benjamin Bloom Pediatric National Hospital